G&A at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's G&A?
- Aurinia Pharmaceuticals (AUPH) reported G&A of $22.03M in Q1 2026.
- How has Aurinia Pharmaceuticals's G&A changed year-over-year?
- Aurinia Pharmaceuticals's G&A increased by 8.3% year-over-year, from $20.34M to $22.03M.
- What is the long-term trend for Aurinia Pharmaceuticals's G&A?
- Over 4 years (2021 to 2025), Aurinia Pharmaceuticals's G&A has grown at a -12.5% compound annual growth rate (CAGR), from $173.54M to $101.79M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.